UK Markets close in 2 hrs 50 mins
  • FTSE 100

    6,358.44
    -32.65 (-0.51%)
     
  • FTSE 250

    19,350.67
    -218.72 (-1.12%)
     
  • AIM

    1,035.58
    +3.82 (+0.37%)
     
  • GBP/EUR

    1.1215
    -0.0013 (-0.11%)
     
  • GBP/USD

    1.3349
    -0.0034 (-0.2523%)
     
  • BTC-GBP

    12,988.67
    -446.27 (-3.32%)
     
  • CMC Crypto 200

    339.41
    -31.10 (-8.39%)
     
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • DOW

    29,872.47
    -173.77 (-0.58%)
     
  • CRUDE OIL

    45.18
    -0.53 (-1.16%)
     
  • GOLD FUTURES

    1,811.30
    +5.80 (+0.32%)
     
  • NIKKEI 225

    26,537.31
    +240.45 (+0.91%)
     
  • HANG SENG

    26,819.45
    +149.70 (+0.56%)
     
  • DAX

    13,299.51
    +9.71 (+0.07%)
     
  • CAC 40

    5,568.02
    -3.27 (-0.06%)
     

Immunicom CEO Amir Jafri Named a Top Healthcare Leader in CEO Today Healthcare Awards

·3-min read

Immunicom, Inc. Founder and CEO, Amir Jafri, has been named one of the top eight healthcare leaders by CEO Today Magazine in its 2020 Healthcare Awards. Jafri was recognized for his vital healthcare contributions in developing novel immunotherapies designed to treat a variety of diseases using Immunicom’s breakthrough Immunopheresis™ technology platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005035/en/

Amir Jafri, Founder and CEO, Immunicom, Inc. (Photo: Business Wire)

The Immunopheresis approach is a therapeutic platform that works outside of the body to treat cancer, inflammatory, renal and autoimmune diseases by removing barriers from the blood that block the immune system from doing its job.

"All too often, terminally ill cancer patients make the painful decision to sacrifice their quality of life and financial security for treatment," said Jafri. "Immunicom is redefining the limits of immunotherapy by designing this unique immunotherapy which is intended to meaningfully improve patients’ quality of life and avoid typical side-effects."

Immunicom’s leading Immunopheresis product, the LW-02 therapeutic device, has U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for stage IV metastatic cancer.

Under Jafri’s leadership, Immunicom recently began its ground-breaking clinical trial at Sheba Medical Center in Israel to evaluate the clinical effectiveness of LW-02 as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor. In June 2019, Immunicom began its first clinical study at Jagiellonian University Medical College to compare the effectiveness of the LW-02 therapeutic device alone and its use in combination with low-dose paclitaxel and carboplatin weekly chemotherapy, versus a control arm of low-dose chemotherapy.

A seasoned healthcare technology executive of more than 25 years, Jafri has made valuable contributions to Fortune 50 companies and his own start-ups. He has successfully managed global, multi-billion-dollar products and is highly experienced with global regulatory environments and commercialization. Jafri has served on the board of various healthcare technology start-up companies and is currently a founding board member at Avive Solutions, Inc., a healthcare technology company developing an automated external defibrillator.

For more information, visit www.immunicom.com or www.immunicom.com/how-it-works to watch an overview of Immunicom’s investigational immunotherapy platform.

Immunicom’s Immunopheresis™ therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the U.S. Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies.

About Immunicom

Immunicom, Inc. is a privately-held medical technology company located in San Diego, California and Houston, Texas, focused on developing innovative, non-pharmaceutical approaches for treating cancer, inflammatory diseases, and autoimmune diseases. Immunicom’s revolutionary blood-filtering technology has the potential to effectively treat a wide variety of cancer types, including those that have not responded to other treatment strategies, including other drug and biological-based immunotherapy options, with possibly fewer side effects. The company seeks to leverage its technology to address unmet medical needs and improve patient access and affordability of cancer and other inflammatory and autoimmune disease treatments around the world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005035/en/

Contacts

Media Contact:
Immunicom, Inc.
Hannah Minton
publicrelations@immunicom.com
657-202-6040